
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor ... Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.33 | 14.798206278 | 2.23 | 2.75 | 2.225 | 2193491 | 2.52004828 | CS |
4 | 1.36 | 113.333333333 | 1.2 | 2.75 | 1.2 | 2190341 | 2.01611973 | CS |
12 | 1.25 | 95.4198473282 | 1.31 | 2.75 | 0.783 | 1483579 | 1.55577236 | CS |
26 | 0.1991 | 8.43322461773 | 2.3609 | 2.75 | 0.783 | 1414846 | 1.77832383 | CS |
52 | -0.45 | -14.950166113 | 3.01 | 3.39 | 0.783 | 1340469 | 2.05418364 | CS |
156 | -11.8 | -82.1727019499 | 14.36 | 47.2508 | 0.783 | 1399248 | 10.02114023 | CS |
260 | -16.09 | -86.273458445 | 18.65 | 47.2508 | 0.783 | 1185162 | 10.19688074 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions